Curatis Secures CHF 1.2 Million to Accelerate Late-Stage Corticorelin Development
核心洞察
Curatis Holding AG (搜索) announced a CHF 1.2 million private placement with a strategic Swiss investor through a convertible instrument.
The funding will primarily accelerate development of the company's late-stage clinical lead product candidate corticorelin.
The transaction involves shares delivered from Curatis' conditional capital and is expected to close within days.
Swiss rare disease specialist Curatis Holding AG (搜索) has secured CHF 1.2 million in funding through a private placement with a strategic investor, providing crucial capital to advance its late-stage clinical program for corticorelin, the company announced on November 21, 2025.
Funding Structure and Terms
Under the definitive agreement, the strategic Swiss investor will subscribe for a convertible instrument that can be converted into shares of Curatis Holding AG (搜索). The shares are expected to be delivered from the company's conditional capital, with the instrument issued at prevailing market conditions. The transaction is anticipated to close within the next few days, subject to customary closing conditions.
Strategic Focus on Corticorelin Development
The proceeds from this private placement will primarily enable Curatis to accelerate the development of corticorelin, described as the company's late-stage clinical lead product candidate. This funding represents a targeted investment in advancing the company's most promising therapeutic asset through its clinical development pathway.
Company Profile and Portfolio
Curatis Holding AG (搜索) operates as a publicly listed company on the SIX Swiss Exchange under the ticker CURN.SW, specializing in the final development and commercialization of treatments for rare and very rare diseases (搜索). The company maintains an extensive commercial portfolio comprising more than 40 products, alongside a robust pipeline of orphan drug products and specialist therapeutics.
The company's business model focuses on addressing unmet medical needs in rare disease populations, a sector characterized by limited treatment options and significant regulatory incentives for drug development. This strategic positioning allows Curatis to leverage orphan drug designations and specialized market dynamics to advance its therapeutic candidates.